CXCR3 and neoplasm: CXCR3 mAb significantly prevented activated CD8α+ T cells from increasing in tumors, but not in lymph nodes, as a result of the anti-PD-L1 mAb treatment (Fig. 5D) and significantly attenuated the tumor growth inhibition of the anti-PD-L1 mAb (Fig. 5E).